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Biallelic variants in the ERCC excision repair 6 like 2 gene (ERCC6L2)
are known to cause bone marrow failure (BMF) due to defects in
DNA repair and mitochondrial function. Here, we report on eight
cases of BMF from five families harboring biallelic variants in
ERCC6L2, two of whom present with myelodysplasia. We confirm
that ERCC6L2 patients’ lymphoblastoid cell lines (LCLs) are hyper-
sensitive to DNA-damaging agents that specifically activate the
transcription coupled nucleotide excision repair (TCNER) pathway.
Interestingly, patients’ LCLs are also hypersensitive to transcrip-
tion inhibitors that interfere with RNA polymerase II (RNA Pol II)
and display an abnormal delay in transcription recovery. Using
affinity-based mass spectrometry we found that ERCC6L2 interacts
with DNA-dependent protein kinase (DNA-PK), a regulatory com-
ponent of the RNA Pol II transcription complex. Chromatin immu-
noprecipitation PCR studies revealed ERCC6L2 occupancy on gene
bodies along with RNA Pol II and DNA-PK. Patients’ LCLs fail to
terminate transcript elongation accurately upon DNA damage and
display a significant increase in nuclear DNA–RNA hybrids (R
loops). Collectively, we conclude that ERCC6L2 is involved in reg-
ulating RNA Pol II-mediated transcription via its interaction with
DNA-PK to resolve R loops and minimize transcription-associated
genome instability. The inherited BMF syndrome caused by bial-
lelic variants in ERCC6L2 can be considered as a primary transcrip-
tion deficiency rather than a DNA repair defect.
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Inherited bone marrow failure (IBMF) syndromes are a clin-ically heterogeneous group of diseases. Affected individuals
present with a variety of hematological complications that in-
clude myelodysplastic syndrome (MDS) and acute myeloid
leukemia (AML). Patients with IBMF often have a variable
number of extrahematopoietic features which have historically
been the cornerstone for defining inherited BMF subtypes (1).
Recognized entities include Fanconi anemia (FA), dyskeratosis
congenita, and Shwachman Diamond syndrome, which are as-
sociated with primary defects in DNA repair, telomere mainte-
nance, and ribosome biogenesis, respectively (1). Increasingly,
through advances in next generation sequencing technologies,
new BMF entities are being identified and characterized. This is
leading to better management of these complex patients as well
as elucidating interesting new biological connections.
We first reported biallelic loss-of-function variants in
ERCC6L2 in patients presenting with BMF and microcephaly
[Mendelian Inheritance in Man (MIM) 615667; ref. 2]. Recently,
several more BMF cases with biallelic variants in ERCC6L2 have
been identified (3–6), some of whom presented with MDS (3, 4).
We have now characterized five families that add to the inherited
BMF entity arising from ERCC6L2 mutations and highlight the
link between bone marrow failure and MDS/AML. We also
provide data on the biological functions of ERCC6L2, which
collectively suggest that this disorder principally arises from a
transcription deficiency.
Results
Patient Characteristics. Through a combination of whole exome
sequencing and candidate gene sequencing (7) (SI Appendix,
Table S1) we have identified eight cases from five families with
biallelic variants in ERCC6L2 (NM_020207.4) (Fig. 1 A and B
and SI Appendix, Fig. S1 and Table S2). Sanger sequencing of
parental DNA confirmed an autosomal recessive pattern of
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inheritance (Fig. 1A). Two of the seven ERCC6L2 variants iden-
tified are reported at low frequency on the Genome Aggregation
Database (accessed January 31, 2018) and interestingly, two other
variants have recently been reported in patients with BMF (4) (SI
Appendix, Table S2). To our knowledge, none of the other variants
identified in these families have been described elsewhere.
All probands presented below the age of 20 y with various forms
of BMF (SI Appendix, Table S3). Specifically, the index case from
family 1 (P1, homozygous Glu923fs) presented with a hypoplastic
bone marrow at 8 y of age. Her family history includes a first cousin
who was diagnosed with hypoplastic anemia and an unspecified
relative with AML (SI Appendix, Table S3). In family 2, the index
case (P2, homozygous Ser699Asn) presented at 4 y of age with mild
pancytopenia. Ser699 lies in the helicase domain of ERCC6L2,
which is highly conserved among vertebrates (SI Appendix, Fig. S2).
His elder brother died at 2 y of age, due to neonatal epilepsy,
apnea, and organ failure. His younger affected sister had hypo-
cellular bone marrow, while his younger brother, 3 y of age, is also
homozygous for Ser699Asn but is asymptomatic. In family 3, the
index case (P3, Gly730fs/Asn1111fs) developed microcephaly by
the age of 6 y and presented with macrocytosis associated with
thrombocytopenia at 17 y of age. The index case from family 4 (P4,
Met1148fs/Arg1266*) presented with bone marrow aplasia at age
2 y. He progressed to MDS and AML with a complex karyotype
containing a deletion of the long arm of chromosome 5 and loss of
one copy of chromosome 18 and a marker chromosome, leading
to fatal complications (SI Appendix, Table S3). His two sisters, who
are both compound heterozygotes, also presented with bone
marrow dysfunction. The index case from family 5 (P5, homozy-
gous Lys985fs) 12 y of age, presented with hypoplastic bone
marrow which progressed to MDS with an abnormal karyotype of
monosomy 7 and trisomy 20. Somatic features of short stature,
café au lait spots, and leukoplakia are also present in this case.
One sibling of the index case, 3 y of age, is homozygous for the
frameshift variant but is asymptomatic. No indication of abnormal
chromosomal breakage was reported in the peripheral blood cells
of all affected individuals, when treated with diepoxybutane or
mitomycin C, excluding a diagnosis of FA (SI Appendix, Table S3).
This strong allelic series, in conjunction with other BMF cohorts
studied to date (Fig. 1 A and B), demonstrate that biallelic mu-
tations in ERCC6L2 can cause an inherited BMF syndrome with
predisposition to MDS and AML (2–4).
Patients’ Cells Are Hypersensitive to Transcriptional Inhibitors.
ERCC6L2 belongs to the SWI/SNF family of ATP-dependent
chromatin remodellers and is known to participate in the DNA
damage response and mitochondrial function (2, 5). It is ubiqui-
tously expressed and has at least two distinct isoforms, a short
form and a long form, which has been called a helicase mutated in
bone marrow failure (HEBO) (5). The isoforms arise by alterna-
tive splicing in exon 14, resulting in replacement of the last Val712
residue of the short form with an 850-aa extension in the long
form. Real time-PCR analysis of both total RNA and poly(A)+
mRNA indicated the presence of long and short ERCC6L2 iso-
form transcripts in both CD34+ hematopoietic stem cell progen-
itors and differentiated lymphoblastoid cell lines (LCLs) from
normal individuals (Fig. 1C). Studies on patient fibroblasts and
A549 cells treated with ERCC6L2 siRNA have shown hypersen-
sitivity to DNA damaging agents that induce double stand breaks
(DSBs) (2, 5). Patient fibroblasts overexpressing the long form but
not the short form of ERCC6L2 show strong resistance to DNA
damage induced by phleomycin (5). Notably in A549 cells,
knockdown of ERCC6L2 induced sensitivity to irofulven, an RNA
polymerase II (RNA Pol II)-interfering agent that triggers the
transcription-coupled nucleotide excision repair (TCNER) path-
way (2). Irofulven inhibits RNA synthesis and specifically activates
TCNER by trapping transcription complexes where RNA Pol II is
engaged (8–10). Here, we show that patient-derived LCLs, avail-
able from three index cases (P1–P3), show hypersensitivity to iro-
fulven as well as to mitomycin C and phleomycin (Fig. 2 A–C). The
sensitivity of the patient’s LCLs to increasing doses of mitomycin C
was significantly higher than that of control, although they were by
no means comparable to that of LCLs from a patient with Fanconi
anemia group G (FANCG) mutant (Fig. 2A). Interestingly patients
were also hypersensitive to the RNA Pol II-interfering agents, 5, 6-
dichlorobenzimidazole 1-β-D-ribofuranoside (DRB), a transcrip-
tion elongation inhibitor and actinomycin D (ActD), a general
transcription inhibitor (Fig. 2 D and E) compared with both the
control and the FANCG patient.
Irofulven and DRB exert similar effects on transcription, by
blocking RNA elongation and inhibiting RNA synthesis (10).
Given that patients’ LCLs were hypersensitive to these transcrip-
tion inhibitors, we next set out to evaluate the effects of defective
ERCC6L2 on global RNA synthesis in intact cells. To do this, we
measured the incorporation of fluorescently labeled 5-ethynyl
uridine (5-EU) into nascent RNA, using a Click-iT RNA Alexa
Fluor 488 kit. An initial treatment with irofulven for 3 h inhibited
RNA synthesis in both patient and control LCLs, as shown at the
zero time point in Fig. 2F. Subsequent labeling of the nascent
RNAs, after release from the irofulven insult, revealed a gradual
recovery of RNA synthesis, which was notably slower in the pa-
tients compared with control and FANCG LCLs (Fig. 2F). The
reduced recovery rate, postirofulven treatment, indicates a tran-
scription deficiency in these ERCC6L2 patients. DRB and ActD
were used as positive controls to test the fidelity of the assay as
they are known to inhibit RNA synthesis by blocking transcription
(SI Appendix, Fig. S3). Moreover, irofulven treatment led to a
significant increase in DSB markers such as 53BP1 (Fig. 2G) and
arrested patients’ LCLs in G2/M phase (Fig. 2H). These results
collectively demonstrate that patients are transcription deficient
and exhibit increased sensitivity to DNA damaging agents. How-
ever, the precise role of ERCC6L2 in regulating transcription and/
or DNA repair remains unclear.
Fig. 1. Biallelic mutations in ERCC6L2 are identified
in BMF cases. (A) Families identified with ERCC6L2
variants, in autosomal-recessive pattern. Genotypes
indicate + for normal and − for mutated alleles.
Affected cases are denoted in black. Family members
harboring biallelic ERCC6L2 variants but with no
disease features are indicated in gray. (B) The vari-
ants identified in this paper are indicated in red on a
diagram of the long isoform (LF) of ERCC6L2, in
which functional domains are annotated. Previously
published mutations are shown in blue. The location
of the short isoform (SF) is indicated. (C) RT-PCR
analysis shows the presence of the long and short
isoforms of ERCC6L2 in EBV-transformed LCLs, A549
cells, and CD34+ hematopoietic progenitors.
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The ERCC6L2 Interactome Includes RNA Binding and Processing
Factors. To further elucidate the primary cellular function of the
long form of ERCC6L2 (NP_064592.2), we sought to identify its
interaction partners. Using an unbiased approach, we performed
affinity-based mass spectrometry (MS) analyses (11) after coim-
munoprecipitation with GFP TRAP beads in soluble extracts from
293T cells overexpressing GFP-ERCC6L2 (Fig. 3A). Data
obtained from MS were analyzed by filtering the interactors
based on the best protein MASCOT scores, the spectral counts,
and the number of unique peptides (>20) combined with an
interaction stringency determined by a Pearson’s correlation
coefficient of >0.99 for GFP-ERCC6L2 over GFP alone (Fig. 3B
and SI Appendix, Table S4). Pathway analysis and visualization of
the resulting proteins (n = 106) using the Uniprot database (12)
and Cytoscape (13) revealed an unexpected role for ERCC6L2 in
RNA binding (14–16) along with its anticipated role in DNA re-
pair and mitochondrial function (2, 5) (Fig. 3 C and D and SI
Appendix, Fig. S4 and Table S5). It had previously been shown
that ectopically expressed ERCC6L2 interacts with NBS1 at DNA
damage foci (5). In agreement with this, we found that NBS1
bound to ERCC6L2, but only with a MASCOT sum score of 260.
This is in stark contrast to the striking interaction observed with
the DNA-dependent protein kinase (DNA-PK, also known as
PRKDC) which had the highest MASCOT sum score (23,361),
number of spectral counts (n = 138), and number of unique
peptides (n = 105) of any protein in the dataset (Fig. 3B and SI
Appendix, Tables S4 and S6). These MS studies therefore show a
close association between ERCC6L2 and DNA-PK and suggest an
additional layer of function for ERCC6L2 in RNA processing.
ERCC6L2 Interacts with DNA-PK to Participate in RNA Pol II-Mediated
Transcription. We confirmed the ERCC6L2 interaction with
DNA-PK in 293T cells overexpressing GFP-ERCC6L2 by
coimmunoprecipitation with GFP TRAP beads and Western
blotting. The stringency of ERCC6L2 interaction with DNA-PK
was not significantly affected by either DNase I or RNase A (Fig.
3D), indicating only a minor involvement of DNA and/or RNA
in mediating this association. Coimmunoprecipitation experi-
ments in HeLa and A549 cells overexpressing GFP-ERCC6L2
confirmed that ERCC6L2 association with DNA-PK is not cell
specific (Fig. 3E).
DNA-PK is involved in several vital functions, including a
crucial role in signaling nonhomologous end joining (NHEJ) or
homologous recombination (HR) in DNA repair (17). However,
it has been shown previously that ERCC6L2 is not required for
either NHEJ or HR (5). DNA-PK also promotes transcription
fidelity by the eviction of RNA polymerase II (RNA Pol II) from
active genes at sites of DNA damage (18). Noting the tran-
scription deficiency observed in patients’ LCLs (Fig. 2 D–F) and
the multiple RNA binding proteins present in our pull-down
experiment (Fig. 3C and SI Appendix, Fig. S4 and Tables S4
and S5), we sought to further investigate the role of ERCC6L2 in
transcription, where both DNA-PK and RNA Pol II are in-
volved. To do this, we performed chromatin immunoprecipita-
tion (ChIP)-PCR assays on chromatin extracts prepared from
293T cells expressing GFP alone and GFP-ERCC6L2 using a
GFP-specific antibody. These revealed the occupancy of GFP-
ERCC6L2 on MYC, FOS, and JUN gene bodies (Fig. 3F), using
the same primer pairs that were used previously elsewhere to
show occupancy of total and phosphorylated forms of DNA-PK
and RNA Pol II on these genes (19). These experiments indicate
that ERCC6L2 associates with DNA-PK and occupies the same
gene bodies along with RNA Pol II.
ERCC6L2 Is Required for Transcriptional Fidelity. Having shown
ERCC6L2 occupancy on gene bodies, we next tested transcrip-
tional fidelity in the available ERCC6L2 patients (P1–P3) by
assessing phosphorylation levels of serine-5 and serine-2 residues
in the heptapeptide repeat (Tyr-Ser-Pro-Thr-Ser-Pro-Ser) in the
carboxyl-terminal domain (CTD) of RNA Pol II. Phosphoryla-
tion on serine-5 of the RNA Pol II CTD indicates transcription
initiation, whereas phosphorylation of serine-2 is a marker of
transcription elongation (20). In the steady state, a reduction in
phosphorylation levels of serine-2, but not serine-5 was observed
in patients’ LCLs compared with control as well as the FANCG
patient (Fig. 4A and SI Appendix, Fig. S5A). This result indicates
that ERCC6L2 plays a role in the elongation of RNA Pol II
transcripts. We also observed a dramatic increase in DNA-PK
catalytic subunit (cs) phosphorylation at serine-2056 in cells from
the ERCC6L2 and FA patients (Fig. 4A), indicating a height-
ened DNA damage response in both diseases. In addition to
these defects in the steady state, patients’ LCLs also showed
abnormal kinetics of serine-2 phosphorylation on RNA Pol II
CTD and serine-2056 phosphorylation of DNA-PKcs when they
were treated with irofulven (Fig. 4B). As expected, we observed a
reduction in serine-2 phosphorylation in control LCLs within
30 min of irofulven treatment (Fig. 4B). However, in the pa-
tients’ LCLs we observed a brief increase in serine-2 phosphor-
ylation on RNA Pol II CTD, indicating a failure of these cells to
stall transcription elongation. This increase of serine-2 phos-
phorylation on RNA Pol II CTD was specific to ERCC6L2 pa-
tients, as the transcription termination kinetics in FANCG cells
Fig. 2. ERCC6L2 deficiency causes transcription
deficits and arrests patients’ LCLs in G2/M phase. (A–
C) Control and patients’ LCLs were plated in the
presence of increasing concentrations of indicated
compounds for 24 h and assayed for cell viability. (D
and E) Compared with control and FANCG LCLs,
patient LCLs showed reduced survival after treat-
ment with DRB and ActD in a dose-dependent
manner. Error bars represent SEs calculated be-
tween octuplets in each individual experiment (n =
2). (F) Control and patient LCLs were incubated with
1 nM irofulven for 1 h and the influence on RNA
synthesis after release from irofulven for the in-
dicated time intervals was measured by incorpora-
tion of fluorescently labeled 5-EU, that was added to
the medium for 15 min. Error bars represent the SEM
obtained from three independent experiments. (G)
53BP1 staining in control and patients’ LCLs at 24 h
postrelease from irofulven treatment. Panels display
53BP1 (red) and DAPI (blue). (Scale bar: 50 μm.) (H)
FACS analysis plots show the cell cycle phases where
pre- and 24-h postrelease from irofulven treatment
arrest patient cells in G2/M phase.






was similar to the normal control (Fig. 4C). At the same time, we
saw an increase in the activation of DNA-PKcs in patients (in-
dicated by phosphorylation at serine-2056) over and above the
increase that was seen in the control (Fig. 4B and SI Appendix,
Fig. S5B). Together, these data indicate that although DNA-PK
is hyperactive in patients’ LCLs, it is ineffective in stalling RNA
Pol II. This results in an increase in transcription-induced DNA
damage and cell cycle arrest (Fig. 2 G and H).
Patients’ Cells Possess an Increased Number of R Loops. During
transcription, nascent RNAs can form hydrogen bonds with one
strand of the DNA double helix, leading to the formation of
DNA–RNA hybrids, known as R loops. Cells utilize diverse
mechanisms to resolve these R loops, either by RNase activity,
that specifically degrades the RNA moiety in RNA–DNA hybrids
or by helicases, such as Aquarius and Senataxin that unwind the R
loops (21). R-loop formation can also be precluded by proteins
that bind to nascent RNAs as they emerge from RNA Pol II (22).
Besides DNA-PK, ERCC6L2 also interacts with other proteins
that are involved in processing of R loops (SI Appendix, Table S7)
(23, 24). Noting these interaction partners, we sought to investi-
gate R loops in patients’ LCLs as they possess transcription-
associated defects that compromise genome integrity. By
immunostaining with S9.6 antibody, which specifically rec-
ognizes DNA–RNA hybrids, we did indeed detect R loops in
both patients and control (Fig. 5A and SI Appendix, Fig. S6).
However, the fluorescence intensity of the DNA–RNA hybrid
signal was increased significantly in the nucleoplasm of the pa-
tients’ LCLs compared with control. This signal was abolished by
pretreatment with RNase H, demonstrating its specificity. Some
weak nucleolar S9.6 signal persisted after RNase H treatment,
and this could be due to the presence of hybrids that are either
resistant to RNase H, or the incomplete action of the nuclease in
nucleolus, where DNA–RNA hybrids are abundant. We excluded
nucleolar signals from our analysis, as the number of nucleoli varied
from cell to cell (SI Appendix, Fig. S6) and concluded that patients
have significantly increased numbers of nucleoplasmic R loops.
To investigate a possible role for replication in this increased
R-loop signal in the ERCC6L2 patients’ cells, we compared
them to the control cells upon serum starvation. This caused the
cells to cease replicating, as demonstrated by the negligible in-
corporation of bromodeoxyuridine (BrdU) (SI Appendix, Fig.
S7). Under these conditions, patient cells still showed significant
increase in R-loop signals, compared with controls (Fig. 5B).
These data suggest that ERCC6L2 is primarily involved in pro-
cessing the R loops generated during transcription. Finally, we
have established a direct role for DNA-PK in R-loop metabo-
lism. Treating control cells for 3 h with NU7026, a potent in-
hibitor of DNA-PKcs phosphorylation activity (SI Appendix, Fig.
S8), resulted in a dramatic increase of DNA–RNA hybrids (Fig.
5C). Patient cells also showed an increase in signal intensity,
above the steady state levels that were already high. This increase
in R-loop signal intensity upon inhibition of DNA-PKcs activity
indicates that transcription elongation is dependent on the ac-
tivity of DNA-PK (18). Collectively our results point to a crucial
role for the interaction between ERCC6L2 and DNA-PK in the
control of transcription and processing R loops.
Discussion
This paper reports on eight cases of bone marrow failure from
five families harboring biallelic variants in ERCC6L2 (Fig. 1 A
and B). Two of the cases (P4 and P5) had MDS, one of whom
progressed to AML (SI Appendix, Table S3). Previous studies
have established a DNA repair defect in A549 cells and patient
fibroblasts that lack ERCC6L2 (2, 5). Here, we show that
patient-derived LCLs also exhibit hypersensitivity to DNA
damaging agents (Fig. 2). We also demonstrate that these pa-
tients’ cells are hypersensitive to RNA Pol II-interfering agents,
particularly irofulven that traps RNA Pol II complexes at DNA
lesions and initiates TCNER. Patient cells are compromised in
DNA repair capacity, as evidenced by 53BP1 staining, have ab-
normal delay in RNA synthesis recovery rates, and fail to accu-
rately stall transcription elongation following irofulven treatment
(Fig. 2). Extending these studies, we have identified a role for
ERCC6L2 in contributing to the DNA damage response through
its interaction with DNA-PK (SI Appendix, Table S4). We show
that the ERCC6L2 interactome not only contains DNA repair
proteins, but is also composed of RNA binding proteins that are
involved in processes such as mRNA elongation, maturation, and
Fig. 3. ERCC6L2 physically interacts with DNA-PK and occupies gene bodies along with RNA Pol II. (A) Colloidal blue staining of GFP and GFP-ERCC6L2
proteins overexpressed in 293T cells and separated by SDS/PAGE. (B) MS analysis for relative protein abundance that is sorted on the basis of highest spectral
counts and ranked by Pearson’s correlation coefficient (Log2 fold change) between GFP-ERCC6L2 and GFP only control. Note the standout signal for DNA-PK.
(C) Pie chart overrepresentation of ERCC6L2 interactome. (D and E) Co-IP followed by Western blot analysis confirm the interaction between GFP-ERCC6L2
and DNA-PK in 293T, A549, and HeLa cells. Lysates were treated with DNase I or RNase A where indicated. (F) ChIP-PCR shows occupancy of GFP-ERCC6L2, RNA
Pol II, and DNA-PK with the MYC FOS and JUN gene bodies. Note the occupancy of all three genes is seen with GFP-ERCC6L2 and not when GFP alone was
expressed. The phosphorylation residues targeted by ChIP antibodies are serine-2056 for DNA-PK and serine-2 for RNA Pol II.
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export (Fig. 3 A–C and SI Appendix, Fig. S4). We also show that
ERCC6L2 primarily interacts with DNA-PK and occupies gene
bodies alongside RNA Pol II (Fig. 3 D–F). Finally, we have
observed an increase in nucleoplasmic R-loop density (Fig. 5A
and SI Appendix, Fig. S6), which could be the root cause of the
genomic instability in these patients (SI Appendix, Fig. S10).
DNA-PK was initially identified as a regulatory component of
transcriptionally poised RNA Pol II (17). Given that transcription
is perhaps the most fundamental mechanism behind cell fate, the
role of DNA-PK in regulating this process, besides DNA repair,
may have critical implications in BMF. Our studies suggest the
ERCC6L2–DNA-PK interaction could be particularly relevant in
the repair of transcription-associated DNA lesions (19). Inter-
estingly, a knockin mouse model harboring defective DNA-PKcs
activity has features of congenital BMF causing premature death
due to inefficient DNA repair (25). One could argue that DNA-
PKcs activity in transcription-associated DNA repair is controlled
via its interaction with ERCC6L2 and this is defective in patient
cells. Collectively our studies support the notion of a primary
transcription defect rather than a DNA repair defect in patients
with BMF harboring biallelic ERCC6L2 variants.
To date, the molecular pathology of IBMF has been attributed
to defects in DNA repair, telomere maintenance, and ribosome
biogenesis (1). Defects in the TCNER pathway have been
reported previously in autosomal recessive disorders, including
Cockayne syndrome (CS) (MIM 133540) and the functionally
related xeroderma pigmentosum (XP) (MIM 278700, 610651,
278720, 278730, 278740, 278760, and 278780) (26). Mutations in
CSA and CSB genes cause CS and to date 70% of CS cases are
linked to mutations in CSB (27). CS is characterized by growth
retardation, retinal abnormalities, progressive neural retarda-
tion, and severe photosensitivity (28). However, only five of the
20 ERCC6L2 mutated cases reported to date have neurological
defects (2, 5, 6) and conversely, there have been no reports of
BMF in cases with CS or XP. Both CSB and ERCC6L2 belong to
the family of SWI/SNF proteins that activate transcription by
facilitating access of the transcriptional machinery to the chro-
matin (29). Recent cryo-EM studies have shown a key role for
RAD26 (the yeast ortholog of human CSB) in TCNER and
RNA Pol II transcription elongation (30). CSB protein is re-
quired for processing R loops at the stalled transcription com-
plexes (31). Both CS cells and ERCC6L2 LCLs are defective in
RNA synthesis recovery and hypersensitive to clastogens that
induce TCNER (32). Failure of the TCNER process also sen-
sitizes CS cells to oxidizing agents that include ionizing radiation
(33). ERCC6L2 patients’ LCLs are also hypersensitive to DNA
damaging agents that induce oxidative stress (Fig. 2 A–C) (2, 5).
Together, these studies indicate that ERCC6L2, like CSB, may
participate as a cotranscriptional regulator, facilitating RNA Pol
II elongation and processing of R loops. Defects in RNA Pol II-
mediated elongation and R-loop accumulation could sensitize
patient cells to persistent DNA damage (Fig. 2 A–C) and explain
the delay in RNA synthesis resumption after irofulven exposure
(Fig. 2F). Another possibility is that when ERCC6L2 is defective,
TCNER is not initiated appropriately, resulting in the accumu-
lation of elongating RNA Pol II complexes at sites of irofulven-
induced DNA damage. This would also explain the increased
sensitivity of patients’ cells to irofulven (Figs. 2C and 4B).
Our MS analysis of proteins that interact with ERCC6L2 (SI
Appendix, Fig. S4 and Table S4) indicates that it is a multifunc-
tional protein. In particular, our studies suggest that ERCC6L2
may act primarily in RNA processing, in addition to its role in
DNA repair. We observed engagement of multiple RNA binding
proteins, including heterogeneous nuclear ribonucleoproteins, as
Fig. 5. RNA–DNA hybrids (R loops) accumulate in the nucleus of patient
LCLs. (A) The graph shows the median of the S9.6 signal intensity, specific for
DNA–RNA hybrids, per nucleus after nucleolar signal removal. (B) The graph
shows the nucleoplasmic S9.6 signal intensity in noncycling control and pa-
tient cells grown in 0.1% FBS. (C) The graph shows the levels of DNA–RNA
hybrids in cells grown in the presence or absence of DNA-PK inhibitor
NU7026 for 3 h. In all graphs, the S9.6 signal intensity was calculated from at
least ∼3,000 cells from different fields of view, indicated by individual points
for each sample from two independent experiments. **P < 0.01 (Mann–
Whitney U test, two tailed).
Fig. 4. Patients’ LCLs are hypersensitive to RNA Pol II-mediated transcription
insults. (A) Immunoblotting of patient LCL lysates (P1–P3), controls (C1–C4),
and a FANCG line (FA) for total and phosphorylated RNA Pol II CTD at serine-2
(indicating transcription elongation) and serine-5 residues (indicating tran-
scription initiation), total, and phosphorylated DNA-PK at serine-2056 (in-
dicating activation) residue and loading control β-actin. (B) Immunoblotting of
control and patient LCL lysates posttreatment with irofulven at indicated time
points using antibodies against total and serine-2 phosphorylated RNA Pol II
CTD, total, and serine-2056 phosphorylated DNA-PK and the loading control
β-actin. (C) Immunoblotting panels show control, FANCG, and patient (P2 and
P3) LCL lysates obtained after irofulven treatment for the indicated times,
using antibodies against serine-2 phosphorylated RNA Pol II CTD and β-actin
loading control.






well as splicing and export factors which coordinate mRNA
maturation and transport (14–16, 34) (Fig. 3C and SI Appendix,
Fig. S4 and Tables S4 and S5). Interestingly, ERCC6L2 also
interacts with key proteins (SI Appendix, Fig. S4 and Table S7),
that are involved in transcription termination and R-loop me-
tabolism (20, 24, 35). Excessive R loops can exacerbate sensi-
tivity to secondary DNA damaging agents and cause genome
instability (SI Appendix, Fig. S10) (36) and we believe this is the
case in ERCC6L2 patient cells. R-loop accumulation has been
previously reported in FA (37). Cells that lack a functional FA
DNA repair pathway possess DNA replication defects due to
persistent R loops and show hypersensitivity to DNA replication
inhibitors. Our patients’ LCLs also displayed sensitivity to both
replication and transcription inhibitors (Fig. 2 A–E), but they do
possess a functional FA pathway as evidenced by mono-
ubiquitination of FANCD2 upon mitomycin C treatment (5). We
believe that the excessive R-loop accumulation in ERCC6L2
patients may arise due to inefficient transcription stalling. In one
possible model, the ERCC6L2–DNA-PK complex, along with
other RNA processing factors, may bind nascent mRNAs and
prevent them annealing back to DNA. Failure to do so results in
persistent R-loop accumulation and defects in transcription (SI
Appendix, Fig. S10). Although a full understanding of the
mechanistic details of this model awaits further investigation, our
work indicates a role for ERCC6L2 in transcription-coupled
DNA repair and R-loop biology.
In conclusion, we reveal a molecular function for ERCC6L2 in
controlling RNA Pol II-mediated transcript elongation via in-
teraction with DNA-PK to resolve R loops and prevent genome
instability. Our genetic and functional data show that pathological
recessive variants in ERCC6L2 perturb transcription elongation
and impede TCNER. This picture is reminiscent of the cellular
defects observed with other chromatin remodellers of the SWI/
SNF family, including CSB (31, 32, 38). However, it remains un-
clear as to why defects in ERCC6L2 function cause bone marrow
failure, while defective CSB does not.
Materials and Methods
Exome and candidate gene sequencing was performed on a series of ge-
netically uncharacterized cases in theDyskeratosis Congenita Registry (held at
Barts and The London School of Medicine, London), with written consent
under the approval of our local research ethics committee (London, City and
East). Transcription assays were performed using a 5-EU labeling kit (Thermo
Fisher). Mass spectrometry was performed in an Orbitrap mass spectrometer
(Q-Exactive Plus). All statistical analysis was done using GraphPad Prism
7 software.
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